#Oncology in bio similar market US | Explore Tumblr Posts and Blogs

kenresearch1 · 11 months

Text

Biosimilars Unleashed: The Future of Healthcare in the US

Buy Now

What is the Size of US Biosimilar Industry?

US Biosimilar Market is expected to grow at a CAGR of ~ % between 2017-2022 and is expected to reach ~USD Bn by 2028. Biosimilars enhance patient access to essential treatments, especially in therapies with high demand, like oncology, by providing more affordable options. Additionally, Growing evidence of biosimilars' comparable efficacy and safety fosters trust among healthcare professionals, driving adoption.

Click here to Download a sample Report

Biosimilars offer cost savings compared to originator biologics, addressing the need for affordable healthcare solutions in the face of rising medical costs. Favorable regulatory frameworks, like the BPCIA, streamline biosimilar approval processes, encouraging manufacturers to invest in development.

Furthermore, The expiration of patents for numerous reference biologics creates opportunities for biosimilar entry, leading to increased competition and market expansion. Pharmaceutical companies are investing in biosimilar R&D and production, expanding the pipeline and market availability. Supportive healthcare policies and reimbursement models incentivize biosimilar adoption, creating a favorable environment for market growth.

US Biosimilar Market by drug class

The US Biosimilar market is segmented by Monoclonal Antibodies, Recombinant Hormones, Immunomodulators, Anti-inflammatory agents and Others. Based on drug class, Monoclonal Antibodies segment dominates the bio similar market in 2022.

Monoclonal antibodies have diverse applications across various therapeutic areas. From cancer treatment to autoimmune diseases, biosimilar Mabs addressed a wide range of medical needs, leading to a broad and growing market. Biosimilars, with their potential for cost savings while maintaining comparable efficacy and safety, gained significant attention as viable alternatives.

US Biosimilar Market by application

In US Biosimilar market, they are segmented by application into Oncology, Blood disorders, Chronic diseases and autoimmune conditions and Others. On the basis of application, Oncology segment was the dominant in 2022.

The increasing prevalence of cancer and the high cost of traditional biologics used in oncology treatment have created a strong incentive for the adoption of biosimilars. Biosimilars offer the potential to provide similar therapeutic outcomes at a lower cost, making them an attractive option for both healthcare providers and patients.

Additionally, the rigorous clinical trials and regulatory processes that biosimilars undergo to gain approval provide reassurance to healthcare professionals and patients regarding their safety and efficacy. This has led to increased acceptance and adoption of biosimilars in oncology.

US Biosimilar by Region

The US Biosimilar market is segmented by Region into North, East, West and South. In 2022, the dominance region is North region in US Biosimilar market.

The North region benefits from a concentration of healthcare providers and academic institutions that are at the forefront of adopting and integrating biosimilars into their treatment protocols. These institutions are more likely to have the expertise to evaluate and incorporate biosimilars effectively, driving their adoption among healthcare professionals and patients.

Click here to Download a Custom Report

Competition Scenario in US Biosimilar Market

The US biosimilar market has witnessed an evolving competitive landscape, with several key players competing for market share. Prominent pharmaceutical companies such as Amgen, Pfizer, Sandoz (Novartis), and Boehringer Ingelheim have been actively involved in developing and marketing biosimilar products. These established players have utilized their expertise in biologics and significant resources to navigate the regulatory landscape and compete effectively.

The competition in the US biosimilar market is characterized by a balance between established pharmaceutical giants and emerging biotech companies. While the major players possess the advantage of resources and experience, smaller biotech firms are also contributing to the market with innovative approaches and niche biosimilar offerings.

What is the Expected Future Outlook for the Overall US Biosimilar Market?

The US Biosimilar market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Billion by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. The US biosimilar market is likely to experience significant growth in the coming years, driven by several factors. Biosimilars are biologic drugs that are highly similar to already approved reference biologics. They offer potential cost savings, increased competition, and improved patient access to crucial treatments.

Firstly, the regulatory environment is becoming more favorable for biosimilars. The Biologics Price Competition and Innovation Act (BPCIA) established a pathway for biosimilar approval in the US, allowing for a smoother regulatory process. As more biosimilars receive approval, competition in the market is expected to intensify.

Secondly, patents for several blockbuster biologics are expiring or have already expired. This creates opportunities for biosimilar manufacturers to enter the market with more affordable alternatives, offering healthcare systems and patients a choice in treatment options.

Thirdly, as healthcare costs continue to rise, biosimilars present an attractive solution for reducing expenses. Their potential to offer cost savings without compromising therapeutic efficacy could lead to increased adoption by healthcare providers, insurers, and patients alike.

Physician and patient education are crucial, as misconceptions about biosimilars' safety and effectiveness might hinder their adoption. Additionally, legal and market access barriers, including patent litigation and complex distribution systems, could slow down the growth of the biosimilar market.

The biosimilar market witness consolidation as larger pharmaceutical companies acquire or partner with smaller biotech firms to bolster their biosimilar portfolios. This will lead to more resources being devoted to biosimilar development and marketing. Changes in healthcare policies, such as reimbursement models and value-based care initiatives, can influence the biosimilar market's growth. Favourable policies that incentivize biosimilar adoption drives their market growth.

0 notes

jayanthitbrc · 5 months

Text

Unlocking Opportunities in Cell Surface Marker Detection Market: Latest Trends and Analysis

Overview and Scope Cell surface marker detection refers to a process of classifying cells based on their markers. Cell surface markers are proteins expressed on the surface of cells or carbohydrates linked to the cell membrane that can be used to identify specific cell types. It is used to categorize cells based on their markers. This information is similar to fingerprints which are unique to each cell type and may be identified based on the kinds of markers present on the membrane. Sizing and Forecast The cell surface marker detection market size has grown strongly in recent years. It will grow from $5.52 billion in 2023 to $6.06 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The cell surface marker detection market size is expected to see rapid growth in the next few years. It will grow to $8.95 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. To access more details regarding this report, visit the link: https://www.thebusinessresearchcompany.com/report/cell-surface-marker-detection-global-market-report Segmentation & Regional Insights The cell surface marker detection market covered in this report is segmented – 1) By Product: Flow Cytometry, Hematology Analyzers, Reagents and Kits 2) By Application: Disease Diagnosis, Diseases Identification, Research for Drug Discovery, Cytological Academic Research 3) By End-Users: Pharmaceutical and Biotechnology Companies, Hospitals and Clinical Testing Laboratories, Academic and Research Institutes, Other End Users North America was the largest region in the cell surface marker detection market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell surface marker detection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. Intrigued to explore the contents? Secure your hands-on sample copy of the report: https://www.thebusinessresearchcompany.com/sample.aspx?id=8619&type=smp Major Driver Impacting Market Growth The increasing number of oncology diseases is expected to propel the growth of the cell surface marker detection market going forward. Cancer is a condition in which some cells develop uncontrollably and spread to other body parts. The adoption of western lifestyles, poor dietary habits, frequent non-vegetarian diets, chemical pollution, and a lack of exercise have all contributed to the rise in cancer cases worldwide. Cell surface marker detection support cancer cell with the point-of-care prediction of patient response to several cancer drugs, thus increasing the demand. Key Industry Players Major companies operating in the cell surface marker detection market report are Thermo Fisher Scientific Inc., Beckman Coulter Inc., Siemens Healthineers, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Sartorius, Becton Dickinson and Company. The cell surface marker detection market report table of contents includes: 1. Executive Summary 2. Market Characteristics 3. Market Trends And Strategies 4. Impact Of COVID-19 5. Market Size And Growth 6. Segmentation 7. Regional And Country Analysis . . . 27. Competitive Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected] Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

aprao22 · 4 years

Text

Top 10 Pharma companies

Top 10 pharmaceutical companies in the world

These are ranked by revenue and market capitalization:

1. Pfizer — $51.8 billion 2. Roche — $50.1 billion 3. Novartis — $47.45 billion 4. Merck — $46.9 billion 5. GlaxoSmithKline (GSK) — $43.6 billion 6. Johnson & Johnson (J&J) — $42.2 billion 7. AbbVie — $33.3 billion 8. Sanofi — $27.8 billion 9. Bristol-Myers Squibb — $26.2billion 10. AstraZeneca — $23.6 billion

1.Pfizer

Pfizer is an American multinational pharmaceutical corporation, headquartered in Manhattan. It develops and produces medicines and vaccines for a wide range including oncology, cardiology, neurology, immunology, and endocrinolog

2.Roche

Hoffmann-Roche AG is a Swiss multinational pharmaceutical company headquarters located in Basel, Switzerland.it operates two divisions: Pharmaceuticals and Diagnostics.

3.Novartis

Novartis AG is a Switzerland multinational pharmaceutical company headquarters located in Basel. It manufactures drugs clozapine, diclofenac, carbamazepine, valsartan, terbinafine, and others.

4.Merck

Merck & Co. is a German multinational pharmaceutical company incorporated in Jersey, United States of America.

5. GlaxoSmithKline ( GSK)

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company headquartered in Brantford, England in 2000.

6. Johnson & Johnson (J&J)

Johnson & Johnson (J&J) is an American multinational company headquartered, New Jersey in 1886. It develops medical devices, pharmaceuticals, and consumer goods.

7. AbbVie

AbbVie is an American multinational corporation biopharmaceutical company founded in 2013. It operates as research-based pharmaceutical products, medical devices, diagnostic equipment, and nutrition products

8. Sanofi

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, founded in 2013. It operates in the R&D, manufacturing, and pharmaceutical drugs' major therapeutic areas are the cardiovascular, central nervous system, diabetes, internal medicine, oncology, and vaccines.

9. Bristol-Myers Squibb

Bristol Myers Squibb is an American multinational pharmaceutical company, located in New York City. It manufactures pharmaceuticals, biologics, therapeutics, oncology, HIV, cardiovascular, diabetes, hepatitis, arthritis, and psychiatric diseases.

10. AstraZeneca

AstraZeneca, is a Britain-Swedan multinational biopharmaceutical company, headquarters in England. It has manufactured major disease areas cancer, cardiovascular, respiratory, and inflammation. In 1999. they merged Swedish Astra AB and the British Zeneca Group.

Top 10 pharmaceutical companies in India

The top 10 pharmaceutical companies in India ranked by revenue and market capitalization:

Rank Industry $Billions ₹Crores

1 Sun Pharma 10.3 75326.63

2 Dr. Reddy’s 7.4 54,223.62

3 Divi’s 6.2 45,023.67

4 Cipla 5.3 38,875.43

5 Aurobindo 4.9 35,641.85

6 Torrent 4.4 32054.46

7 Lupin 4.2 30362.52

8 Zydus Cadila 3.5 25325.64

9 Abbott India 3.1 22624.21

10 Alkem 2.5 18584.54

India is the largest provider of generic medicines, holding a market share of 25% to worldwide supply by volume and meets 61% of the vaccine requirement around the world. Indian pharmaceutical companies also supply 81% of antiretroviral medications (HIV/AIDS) in the worldwide markets.

The international pharmaceutical market is anticipated to surpass USD 1.2Trillion by 2022. India is one most suitable states in this worldwide pharma market. India provides more than 55% of the worldwide purpose for different vaccines and 45% of the demand for generic medicines in the United States. India’s pharmaceuticals demanded to expand at 11% CAGR during 2023 to reach 33 Billion US dollars.

1. Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company founder Dilip Shanghvi in 1983, Vapi, Headquarters Goregaon, Mumbai, India, And Subsidiaries Ranbaxy Laboratories, etc...It produces and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India also the United States. Sun Pharma provides formulations in psychiatry, cardiology, dialectology, neurology, and gastroenterology. The company supplies APIs such as etodolac, clorazepate, carbamazepine, warfarin, and anti-cancer drugs, peptides, steroids, sex hormones, etc. Sun supplies more than 2000 formulations and also exports in various other countries. The main features of Sun Pharmaceuticals are research and development facilities and its own API’s

2. Dr. Reddy’s Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is an Indian multinational pharmaceutical company founder Kallam Anji Reddy in 1984, Hyderabad, India. The company produces pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and other countries and more than 195 drugs, 65 APIs for drug, biotechnology products. DRL has six APIs(CTO)and four Formulations(FTO)manufacturing plants across India. Its main focus research and development centers are Integrated product development Organization(IPDO) and Custom Pharmaceutical Services(CPS) located in Hyderabad, India.

3.Divi’s Laboratories Ltd

Divis Laboratories Ltd is an Indian pharmaceutical company founder Murali Divi in 1990, Hyderabad, India. It manufactures APIs, Intermediates, and Nutraceutical ingredients. Divis Labs have three manufacturing units located at Chouttal, Hyderabad, Chippada, A. Andhra Pradesh, and 3 Research and development centers. The Company exports the products to the USA, Europe, Japan, South Africa, Australia, and the Philippines.

4. Cipla Ltd

Cipla is an Indian multinational pharmaceutical company founder Khwaja Abdul Hamied in 1935, Headquarters Mumbai, India, And supplies top-quality generic medicines in India The company supplies a wide range of medicines. It has got a prominent position in the Indian market ad global market and more than 150 countries. The company provides quality products worldwide received approvals from major regulatory agencies and more than 2000 formulations cover areas like neurology and nephrology. Cipla has a global focus on the important markets of India, the US, and South Africa.

5.Aurobindo Pharma Ltd

Aurobindo Pharma is an Indian pharmaceutical company founder Nityananda Reddy started operations in 1988 with a single unit manufacturing Synthetic Penicillin at Pondicherry after became a public company in 1992 headquartered in HITEC City, Hyderabad, India. the company has provided key therapeutics like cardiovascular, antiretrovirals, antibiotics, gastroenterology, anti-diabetics, anti-Allergics. The company exports products to more than 160 nations in the world. Aurobindo pharma has production, research, and development and Subsidiaries units are Novagen Pharma, AuroZymes Ltd, etc

6. Torrent Pharmaceuticals Ltd

Torrent Pharma an Indian pharmaceutical company founder Uttambhai NathalalMehta in 1959 Headquarters Ahmedabad, India. started as Trinity Laboratories Ltd, and renamed Torrent Pharmaceuticals Ltd. nowadays, it is ranked leaders in the therapeutic sector of the women’s health care, cardiovascular, CNS, gastrointestinal, diabetology, oncology, gynecology, and anti-infective. They have first-class manufacturing units, R & D facilities, and a prevalent international presence in more than 50 nations. The company had procured the Elder Pharma’s Indian company, Zyg Pharma, the API plant of Glochem Industries, Unichem’s Sikkim Plant, Bio-Pharm Inc, generic pharmaceuticals, etc.

7. Lupin Ltd

Lupin is a multinational pharmaceutical company founder Desh Bandhu Gupta in 1968 Mumbai, India a large range of products like Branded & Generic Formulations, Biotechnology Products, APIs, and manufacturing centers are across India, Japan, Brazil, Mexico, and the United States. Subsidiaries are Novel Laboratories, Polynova Industries, and GAVIS Pharmaceuticals. The company is in treatment areas of Non-Steroidal Anti-Inflammatory Drugs, Cardiovascular, Gynaecology, Asthma, Paediatric, Diabetology, Gastro-Intestinal, and Anti-Infective drugs, Anti-TB and Cephalosporins sectors. The company is moved around more than 100 countries. It supplies top quality medications.

8.Zydus Cadila Healthcare Ltd

Zydus Cadila is a Zydus Cadila, is a fully integrated Indian Pharmaceutical company founded by Ramanbhai B. Patel in 1952 in Ahmedabad, Gujarat India. It provides active pharmaceutical ingredients, formulations, and animal healthcare products to wellness products. The company’s research and development facilities are in Gujarat, Maharashtra, Goa, Himachal, and Sikkim also research units in the US and Brazil. It has 1400 researchers across 20 sites, working on medicines and exploring various ideas from NCEs to vaccines, bio-similar products. The company’s global business has regulated markets of the United States, Europe, South Africa, Latin America, and also 30 other national markets in the world.

9. Abbott Pharma India Ltd

Abbott India Limited is a Pharmaceutical company founder Dr. Wallace Calvin Abbott in 1944, Mumbai, India, and a subsidiary of Abbott Laboratories United States. It manufactures pharmaceutical drugs, therapeutics Women’s Health, Neurology, Thyroid, Gastroenterology, Anti-Infective, Diabetes, Urology, Pain, Vitamins, etc., and a plant at Verna, Goa. Abbott has to produce high-quality formulations, branded generic pharmaceuticals, diagnostics, medical devices, and nutrition.

10. Alkem Laboratories Ltd

Alkem Laboratories is a Pharmaceutical company founder Samprada Singh in 1973, Mumbai, India. It provides quality branded generics, generic medications, APIs, nutraceuticals in India, and more than 60 countries around the world. Alkem Laboratories has been ranked as the No.1 Anti-infective company in India for more than ten years also therapeutic segments of gastrointestinal, Vitamins, Minerals, Nutrients, and pain management.

#Best pharma industries #Top 10 pharmaceutical companies

1 note · View note

healthcare-domain · 2 years

Text

Tissue Diagnostics Market Size, Share | 2022 - 2027 | MarketsandMarkets

COVID-19 positively impacted the market due to a growing demand for high-throughput and sequencing-based diagnostic tests. For instance, Brooks Automation’s Life Science segment reported USD 199.6 million in revenue in 2021, compared to USD 129.8 million in 2020, with an increase of USD 69.8 million (54%). Likewise, in 2021, the revenue of Roche Diagnostics increased by 28% due to COVID-19.

The number of cancer screening and diagnostic procedures declined precipitously, with countries worldwide being affected by the pandemic. An initial analysis of the US market shows that newly diagnosed metastatic non-small-cell lung cancer patient volumes have declined just over 30% from February 2020 to March 2020 — this represents a major decline in just one month. This also impacted KRAS, BRAF, and EGFR testing rates, which are the key biomarkers supporting the appropriate selection of precision medicine therapies that benefit certain patients.

The interim Chief Medical Officer of Scotland reported that the urgent referrals of patients with cancer by primary-care physicians had been reduced by over 70% by mid-April compared with the weekly average over the past three years. Similar reductions have been reported in England. Assuming urgent cancer referrals have a conversion rate of 7%, Cancer Research UK has estimated that this reduction in referrals could mean around 2,000 fewer cancers are being diagnosed per week.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1063949

[246 Pages Report] The global Tissue Diagnostics market is growing at a CAGR of 6.6% during and it is expected to reach USD 7.3 billion by 2027 from USD 5.3 billion in 2022, during the forecast period. The expansion of this market is majorly due to rising prevalence of neoplastic cases as well as high demand of oncology screening, However, Lack of skilled professionals is one of the challenge for which may inhibit the growth of this market.

Additionally, the closure of manufacturing facilities disrupted supply chains and reduced recruitments. For instance, in the UK, universities, sponsors, charities, NHS institutions, and NIHR Clinical Research Network decided to stop all non-COVID-related research in March 2020 and to pause the setup of new trials too. However, in the 2022 recovery phase, restoring clinical trials will be a challenge because of restricted access at trial sites.

Soon as the FDA implemented regulatory cautions regarding how digital pathology systems could be used during the pandemic, many pathologists started working flexibly in remote locations to minimize the COVID-19 exposure risks and provide timely diagnoses. As a result, the tissue diagnostics market rose to a high extent.

In conclusion, the emergence of new variants of COVID will increase the demand for new clinical trials to identify and evaluate the effectiveness of drugs against COVID-19 during the forecast period.

Some of the major players operating in Tissue Diagnostics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), and Hologic Inc. (US).

1 note · View note

gyrussystemm · 3 years

Text

Global Oncology Biosimilar Treatment Market – Past, present, and way forward

Biosimilar or bio generics are bio therapeutic products with large and complex structures that are similar to their innovator product in all aspects including their safety, efficacy, and quality.

There is a palpable sense of urge among researchers and pharmaceutical industries to develop biosimilar for treatment, with its popularity expected to rise in the forthcoming years especially in developing low-cost biosimilar that are easily accessible and affordable for patients.

Market trends show that North America continues to dominate the global oncology biosimilar market followed by Europe, Asia Pacific, Latin America, Middle East, and Africa. The market is purported to reach approximately USD 45 Billion in the year 2026 from the current market of approximately USD 6 Billion.

Understanding the local and global market demand is necessary for companies, research institutes, and investors to study the changing dynamics in the biosimilar market. Segmentation of biosimilar by product, type of cancer, as well as targeted end-user such as hospital/online/retail pharmacies is particularly useful in empowering industries to make informed business decisions. Product segmentation also helps gauge the project’s feasibility so that the pharmaceutical industry can focus on developing safe and commercially viable products. Comprehensive analyses, robust legal and regulatory frameworks, continuing medical education for health care professionals and increased awareness among the public will undoubtedly increase the uptake of biosimilar and help the biosimilar market move ahead competitively.

0 notes

techsciresearch · 3 years

Text

Optical Genome Mapping Market to Grow with an Impressive CAGR During the Forecast Period | TechSci Research

Modern medicine evolution is driving the growth in Global Optical genome mapping Market in the forecast period, 2022-2026.

According to TechSci Research report, “Global Optical Genome Mapping Market By Component (Instruments v/s Consumables) By Application (Genome Assembly, SV Detection, Microbial Strain Typing, Haplotype Phasing, Others) By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Clinical Laboratories, Others) By Region, Competition Forecast & Opportunities, 2026”, the global optical genome mapping market may potentially project an impressive growth in the forecast period, 2022-2026, with an impressive CAGR on the account of enhancing microbiological methods for various medical procedures.

Bio-pharmaceutical advances for the latest drug development and genome manipulation for enhancement of other treatment methods and instruments is driving the growth of the global optical genome mapping market in the upcoming five years. Moreover, increased advancement in the biotechnological methods, and bioinformatic processes is further aiding the growth of the market in the next five years. Additionally, advancing methods of healthcare, medicine research, biotech evolution along with technological advancement for various kind of diagnostic tests are further substantiating the growth of the global optical genome mapping market in the future five years of forecast until 2026.

Optical genome mapping is a biotechnical procedure of constructing ordered, genome-wide, high-resolution restriction maps from single, stained molecules of DNA, called optical maps. The complete procedure involves a complex process of DNA barcoding, template nicking, gap formation, fluorochrome incorporation, imaging, and photo bleaching along with repeated cycle of fluorochrome incorporation and photo bleaching. The process is less time consuming and is less costly as compared to similar usability biotechnological processes.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Optical genome mapping Market"

https://www.techsciresearch.com/report/optical-genome-mapping-market/7731.html

The global optical genome mapping market segmentation is based on component, application, end user, competitional landscape, and regional distribution. Based on application, the market is further bifurcated into genome assembly, SV detection, microbial strain typing, haplotype phasing, and others. Genome assembly is an application of optical genome mapping in the field of bioinformatics, where the computational process of resolving the sequence composition of the genetic material (DNA) within the cell of an organism. SV detection or structural variation analysis are genomic alteration that involves larger DNA segments often more than 1 Kb, (Kilobase). Advancing biotechnological advances for the healthcare evolution is driving the growth of the global optical genome mapping in the next five years.

Based on component, the market is further divided between instruments and consumables. Optical genome mapping plays major part in drug development procedures thus, consumable component can be expected to hold the largest revenue shares of the market segment and assert its dominance over the segment in the upcoming five years. Diagnostic prenatal testing for the detection and prevention of genetic disorders optical genome mapping is a novel method is able to detect all classes of structural variations (SVs), including copy number variations (CNVs) and thus provide better testing instruments and testing kits.

The market is expected to support significant growth in the upcoming five years. For example, Irys Instrument reveals genome structure by performing low-cost next-generation mapping at single-molecule resolution. Irys provides the long-range genomic information required for high-quality de novo assembly and high-resolution discovery of structural variations. These next-generation mapping tools along with next-generation sequencing, can be used especially for building reference genomes.

Holding the major shares of the global optical genome mapping market are OpGen, Inc., Bionano Genomics, Inc., Nabsys Inc, Nucleome Informatics Pvt Ltd, France Génomique, among others. Market players are actively involved in the research and technological development in the product developments. The advanced technology has made it possible for the industry to provide excellent services through optical genome mapping. Further advancement would aid the market value and brand establishment in the future five years. New market players may focus on the research and development to provide options that satisfies the consumer demand as well as benefits the market players in building their brand value. Other competitive strategies include mergers & acquisitions and new product developments.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7731

Customers can also request for 10% free customization on this report.

“North America is anticipated to be the most volatile and most promising market in the future five years. High prevalence of optical genome mapping instruments and related products and their surging demand is anticipated to aid the growth of the market in the upcoming five years. Also, the region consists of the United States and Canada likewise major economies that support excellent research and biotechnological studies for various purposes and the presence of multiple market players that hold major shares of the market are other major factors that is expected to support the growth of the market too. Consistent research and technological advancement may support the new market players trying to enter the market in the future five years and in their brand establishment,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.

“Global Optical Genome Mapping Market By Component (Instruments v/s Consumables) By Application (Genome Assembly, SV Detection, Microbial Strain Typing, Haplotype Phasing, Others) By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Clinical Laboratories, Others) By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global optical genome mapping and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global optical genome mapping market.

Browse Related Reports:

Global Neuroendocrine Tumor Market By Therapy Type (Chemotherapy, Immunotherapy, Hormonal Therapy, Surgery, Targeted Therapy, Others) By Mechanism of Action (Somatostatin Analogs, Tyrosine Kinase Inhibitor, Peptide receptor radionuclide, Alfa-interferon, Proton pump inhibitors, Others) By Drug Type (Everolimus, Sunitib malate, Lorlatinib, Nivolumab, Bevacizumab, Others) By Indication (Gastrointestinal NET, Lung NET, Pancreatic NET, Appendiceal NET, Others) By Route of Administration (Oral, Parenteral, Others) By End User (Hospitals, Ambulatory Surgical Centers, Oncology Centers, Others (GI centers, Cardio-thoracic centers, NET centers) By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/neuroendocrine-tumor-market/7606.html

Global Nanopore Sequencing Market By Product (Consumables v/s Instruments), By Nucleotide Sequenced (DNA v/s RNA), By Type (Direct Current Sequencing, Synthetic DNA and Horizontal Tunnelling Current Sequencing, Optical Reading Techniques Sequencing, Exonuclease Sequencing), By Type of Nanopore (Solid State, Biological, Hybrid), By Application (Human Genetics, Clinical Research, Plant Research, Microbiology, Animal Research), By End User (Biotechnology Companies, Clinical Laboratories, Academic & Research Institutes), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/nanopore-sequencing-market/7677.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Optical Genome Mapping Market #Optical Genome Mapping Market #Optical Genome Mapping Market Size #Healthcare #Biotechnology #Optical Genome Mapping Market Forecast

1 note · View note

techscimarketresearch · 3 years

Text

Optical Genome Mapping Market to Grow with an Impressive CAGR During the Forecast Period | TechSci Research

Modern medicine evolution is driving the growth in Global Optical genome mapping Market in the forecast period, 2022-2026.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Optical genome mapping Market"

https://www.techsciresearch.com/report/optical-genome-mapping-market/7731.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7731

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/neuroendocrine-tumor-market/7606.html

https://www.techsciresearch.com/report/nanopore-sequencing-market/7677.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Optical Genome Mapping Market #Optical Genome Mapping Market #Optical Genome Mapping Market Size #Optical Genome Mapping Market Forecast #Healthcare #Biotechnology

1 note · View note

newmarketplace · 3 years

Text

How Would The Generic Oncology Drugs Market Fare In The Next Decade?

Anticipated to surpass the US$ 20 Billion mark in 2019, generic oncology drugs will witness increased demand in the coming years

Increased spending in cancer-related research and development by various governments and private and commercial organizations combined with investments in anti-cancer drugs are the two key factors anticipated to heighten the generic oncology drugs demand, through 2019, as indicated in a recent market analysis of generic oncology drugs, by Persistence Market Research (PMR). Expanding at a robust annual rate of over 6.1 percent, the global revenue through sales of generic oncology drugs will surpass US$ 23 Billion in 2021.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25480

Company Profiles

Novartis AG

Pfizer Inc.

GlaxoSmithKline plc

CELGENE CORPORATION

Teva Pharmaceutical Industries Ltd.

Merck & Company, Inc

Aurobindo Pharma.

Hikma Pharmaceuticals PLC

Mylan N.V.

NATCO Pharma Limited.

Others.

“PMR estimates that notable product pipeline for generic oncology drugs is expected to drive lucrative business opportunities. Moreover, with industry’s pipeline reaching a historic level of late-stage development, in 2017, almost 90% of the therapies being targeted treatments and clinical success rates going up to almost 73 percent, the market for generic oncology drugs is anticipated to grow, further expanding the pipeline cancer treatment”, explained a senior research analyst.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25480

Small Molecule Generic Oncology Drugs Hold Big Opportunities in 2019

Expanding at a rather high CAGR of nearly 6.7 percent, small molecule generic oncology drugs, combing the efficacies of chemotherapy and immunotherapies could boost the ongoing cancer treatment modalities.

Although, there has been a significant development in immunotherapy alone, small molecules are expected to exceed the efficacies of large molecules and dominate the cancer treatment landscape as medical exerts continually validate the positive outcomes by combing traditional cancer treatment with new immunotherapies, thereby providing increased benefits to cancer patients.

Although PMR analysis indicates a relatively lesser market share compared to market molecules, as a modality, small molecules are likely to benefit from their cross-membrane ability, reaching greater intracellular targets.

Moreover, with a half-life of less than 24 hours, small molecules generic oncology drugs are more likely to achieve greater efficacy after a more convenient oral administration, thereby allowing researchers and clinicians to balance the side effect of combination trials through intermittent cancer treatment dosing.

“Research also indicates that more than a quarter of immune-oncology clinical trial use small as combination partners for checkpoint inhibitors, positioning itself as a unique compound class for superior immune-oncology treatments”, explains the analyst.

Potential Revenue Pockets in Emerging Economies

The generic oncology drugs landscape expanding at a robust annual growth rate of approximately 7.5 percent, APECJ along with is anticipated to present significant revenue generating avenues for drug manufacturing companies.

Increased research and development on biological and targeted drug therapies, early expiration of patents, and increasing focus on personalized treatment medication are some major factors contributing towards future avenues for generic oncology cancer drugs market in APECJ. In Japan, on the other hand, stringent regulations involving drug discovery and development process could put a spanner in generic oncology drugs market growth.

“Increasing awareness and growing demand for early cancer diagnosis is expected to translate into homegrown generic oncology drugs, thereby presenting revenue generating opportunities for local drug manufacturers. Favorable reimbursement schemes for critical drugs and significant funding for drug manufacturing infrastructure by government and private organizations of emerging economies are some key factors supplementing to the sales of generic oncology drugs. In addition, contract manufacturing initiatives for biopharmaceuticals and small molecules could broaden the future scope of generic oncology drugs”, the senior analyst further explains.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25480

Product Pipeline Expansion to Remain the Core Forward Strategy

Novartic AG, has applied channel integration strategies such as e-commerce along with the mobile app to drive sales at retail locations. Moreover, the company recently gave global rights of AKT inhibitors afuresertib and uprosertib — to the Shanghai-based company Laekna. In addition, Novartis AG received CE mark for gene-modifying therapy for blood cancer Kymriah.

Pfizer Inc., on the other hand, is focused on 39 therapies in R&D pipeline for oncology and bio similar to strengthen the core areas of the product portfolio. In 2017, Pfizer’s Glasdegib in patients with previously untreated acute myeloid leukemia received U.S FDA priority review. In the same year, company’s XTANDI (enzalutamide) too received FDA approval.

About us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Persistence Market Research Address – 305 Broadway, 7th Floor New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – [email protected]

#Generic Oncology Drugs Market Analysis #Generic Oncology Drugs Market Demand #Generic Oncology Drugs Market Development #Generic Oncology Drugs Market Forecast #Generic Oncology Drugs Market Trends #Generic Oncology Drugs Market Supply

0 notes

atomicjellyfishdelusion · 4 years

Text

Affinity Chromatography Resins Market Status By Current Trend And Future Plan -2028

The process of separation of mixture of colored compounds into individual components is called chromatography. Resins form an important component of chromatographic techniques; they are used in gel filtration, affinity, Ion exchange, hydrophobic interaction, size exclusion and mixed mode chromatographic techniques. Chromatography resins are used for the purification of monoclonal antibodies, affinity tagged proteins, and other bio-molecules. They are used for various purification of wide variety of enzymes and proteins such as albumin purification. The demand for chromatography resin has been increased for monoclonal antibody production that is used in therapeutic areas like oncology, tuberculosis, and autoimmune diseases. This monoclonal antibodies are in demand due to ease of availability and low cost.

More insightful information | Request a sample copy @ https://www.trendsmarketresearch.com/report/sample/3005

Affinity chromatography method is largely preferred for isolation of minor milk proteins from complex protein mixtures on a laboratory scale. Apart from it, its demand has been rising as a separation technique in other food applications as well. This growth in affinity chromatography is directly driving the affinity chromatography resins market. Furthermore, rising demand of affinity chromatography resins for therapeutic antibodies, bio-similar, disposable pre-packed columns, and increasing R&D investments in the pharmaceutical and biotechnological industry is also facilitating its growth across several countries in the world.

Checkout Inquiry to Buy or Customize Market @ https://www.trendsmarketresearch.com/checkout/3005/Single

On the basis of region, the global affinity chromatography resins market can be segmented into North America, Europe, Asia Pacific, Middle East and Africa, and South America. Amongst all, North America and Europe is expected to be the most lucrative affinity chromatography resins market owing to favorable government initiatives and increasing demand in pharmaceutical, biotechnological, and healthcare sector for drug development in the region.

The key players operating in global affinity chromatography resins market are Pall Corporation, Agilent Technologies, Illumina Inc, Affymetrix Inc, Tokyo Chemicals Industries Co. Ltd., Siemens AG, Bio-Rad Laboratories Inc., E-Chrom Tech, Tosoh Corporation, Sigma-Aldrich Inc., PerkinElmer Inc., BASF AG, Jasco Inc., Techcomp Ltd., Merck KGaA, and F. Hoffmann-La Roche Inc., among others.

Talk to our Analyst / Ask for a discount on Market and Get More Information Related to This Report@ https://www.trendsmarketresearch.com/report/discount/3005

0 notes

network-blr · 4 years

Text

Global Kidney Cancer Drugs Market : Industry Analysis and forecast 2019 – 2027: By Type, Therapy, Distribution Channel, and Region.

Global Kidney Cancer Drugs Market size was valued US$ XX Bn. in 2019 and the total revenue is expected to grow at XX% from 2019 to 2027, reaching nearly US$ 7.5 Bn.

The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Kidney cancer also called renal cancer, affects kidney cells to grow out of control and limit the function of normal cells. It is one of the sixth common cancers observed in men and the tenth most common cause of cancer for women. The two main types of kidney cancer are Transitional Cell Carcinoma (TCC) and Renal Cell Carcinoma (RCC) of the renal pelvis.

The MMR report covers all the trends and technologies playing a major role in the growth of the kidney cancer drugs market over 2019-2027. It also highlights the drivers, restraints, and opportunities expected to influence market growth during the forecast period. Major companies operating in the market are focusing on commercial expansion and clinical collaboration present in the market. Stringent governmental regulation makes kidney cancer drugs market tough for small players. A small player or new startup companies in the market are launching various bio-similar products in order to satisfy the growing demand from the emerging economies of the world. On the other hand, lack of appropriate regulatory standards for drug prescriptions and preferences of people for cost-effective generic kidney cancer drugs are major factors expected to hinder the growth of the global market for kidney cancer drugs over 2019-2027.

By therapy, immunotherapy segment was valued US$ XX.22 Mn in 2019 and is expected to reach US$ XX.40 Mn by 2027 at a CAGR of XX.32% over the forecast period. Introduction of advanced drugs, for example, immunotherapy and immune-oncologic are expected to increase the adoption rate as these new drugs are more effective than targeted therapies to a precise patient subpopulation.

The report offers a brief analysis of the major regions in the global kidney cancer drugs market, namely, Europe, North America, Asia-Pacific, Middle East & Africa, and Latin America. North America is expected to continue to hold the largest XX% share in kidney cancer drugs. This is owing to an increased base population of kidney cancer, and a large presence of main drug manufacturers in the USA, which are responsible for launching new drug medication for kidney cancer or renal cancer.

As per the American Cancer Society study in the U.S., approximately 63,990 adults’ new cases of kidney cancer will be diagnosed. The average age of diagnosis is 64 and is hardly found in people less than 45. It is projected that nearly 66% of people are diagnosed when the cancer is only located in the kidney and the five-year survival rate is 92% in this group. The incidence of renal cell cancer is observed highest in Europe and North America. Approximately 59% of kidney cancer cases are observed in developed economies. Thus, increasing the incidence of kidney cancer and the entry of new drug treatment are the key factors contributing to the growth of the kidney cancer drug market globally.

The report covers key developments in the kidney cancer drug market as organic and inorganic growth strategies. In November 2018, Roche Company has withdrawn an application to the European Medicines Agency (EMA) for extended use for its immunotherapy drug, Tecentriq. The Swiss pharma firm had been learning the effects of programmed death-ligand 1 (PD-L1) inhibitor Tecentriq in combination with Avastin to treat kidney cancer.

The objective of the report is to present a comprehensive analysis of the Global Kidney Cancer Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Kidney Cancer Drugs Market dynamics, structure by analyzing the market segments and projects the Global Kidney Cancer Drugs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Kidney Cancer Drugs Market make the report investor’s guide.

Global Kidney Cancer Drugs Market Request For View Sample Report Page :@https://www.maximizemarketresearch.com/request-sample/66282

Scope of the Global Kidney Cancer Drugs Market

Global Kidney Cancer Drugs Market, by Type

• Inlyta (Axitinib) • Afinitor (Everolimus) • Votrient (Pazopanib) • Sutent (Sunitinib) • Nexavar (Sorafenib) • Avastin (Bevacizumab) • Torisel (Temsirolimus) • Proleukin (Interlukin-2/Aldesleukin) Global Kidney Cancer Drugs Market, by Therapy

• Targeted Therapy o Approved drugs o Pipeline drugs • Chemotherapy • Immunotherapy Global Kidney Cancer Drugs Market, by Distribution Channel

• Hospital Pharmacies • E-commerce • Drug stores • Retail pharmacy Global Kidney Cancer Drugs Market, by Region

• Asia Pacific • North America • Europe • South America • Middle East & Africa Key players operating in the Global Kidney Cancer Drugs Market

• Bayer • Amgen • Novartis • Roche • Active Biotech • GlaxoSmithKline • ArQule • Abbott Laboratories • Pfizer • Argos Therapeutics • Exelixis • Cipla Limited • AVEO Pharmaceuticals • Onyx Therapeutics • Genentech • Cerulean Pharma • Bionomics • immatics biotechnologies • Bristol-Myers Squibb • Oxford BioMedica • Wilex • Tracon Pharmaceuticals • Taiwan Liposome • Prometheus Laboratories • Seattle Genetics

Global Kidney Cancer Drugs Market Do Inquiry Before Purchasing Report Here @ :https://www.maximizemarketresearch.com/inquiry-before-buying/66282 About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info: Name: Vikas Godage Organization: Maximize Market Research Pvt.Ltd.Pune Email: [email protected] Contact: +919607065656 / +919607195908 Website:www.maximizemarketresearch.com

#Kidney Cancer Drugs Market

0 notes

kenresearch1 · 11 months

Text

Top 5 players in US Biosimilar Market

Buy Now

STORY OUTLINE

Pfizer: Excelling in the line of Biosimilar drugs with an experience of more than 10 years with presence in over 180 countries.

Amgen: Making pharmaceutical products with an experience of over 40 years and presence in over 100 countries.

Viartis: Presence in over 165 countries, and making Biosimilar drugs in over 75 markets, this pharmaceutical company is another leading contributor of US Biosimilar market.

Coherus Biosciences: Increasing patient access to cost effective medicines with a Biosimilar drugs experience of 13 years.

Biogen: serving humanity through science with a experiences of more than 40 years in the field of biologics.

According to Ken Research, the US Biosimilar market is anticipated to grow at a CAGR of ~40% in the next five years which currently has a market size of ~USD 9.4 Bn.

The US Biosimilar market is rapidly growing and will be witnessing a significant growth in the next five years.

There are various reasons behind the rapid growth of US Biosimilar market. Some of the major reasons behind the growth of US Biosimilar market include the cost effective nature of Biosimilar drugs, rising geriatric population, rising prevalence of chronic diseases, and growing partnerships between companies to develop Biosimilar drugs.

Various companies and players are contributing to their best efforts in the growth of the US Biosimilar market.

This article aims to put light on the contributions done by the major players towards the growth of the US Biosimilar market.

1.Pfizer

Click to read more about Pfizer

Pfizer is a leading American pharmaceutical company which is operating in the field of generics or original drugs for more than 30 years. But did you know that this pharma not only manufactures biologics but also biosimilar drugs?

Pfizer has been in the business of biosimilar drugs for more than 10 years and have been quite successful as well. With more than 83,000 employees and presence in over 180 countries, this leading pharmaceutical company made almost USD 2 Bn. revenue only from its Biosimilar drugs sale in 2021.

Recently, this pharmaceutical company also collaborated with Samsung in two deals to produce various biosimilar drugs in South Korea. The deal size between these two companies happens to be approximately USD 900 Bn.

The major Biosimilar drugs of this pharmaceutical giant are primarily

ZIRABEV (a Biosimilar of Avastin)

TRAZIMERA (a Biosimilar of Herceptin)

RUXIENCE (a Biosimilar of Rituxan)

RITACRIT (a Biosimilar of Epogen)

NVYEPRIA (a Biosimilar of Neulasta)

NIVESTYM (a Biosimilar of Neupogen)

FILGRASTIM (a Biosimilar of Neupogen).

2.Amgen

Click here to Download a Sample Report

Amgen is another leading American pharmaceutical company which not only makes Biologics or generic drugs but also Biosimilar drugs. This pharmaceutical company has more than 40 years of experience when it comes to pharmaceutical line.

With over 25000 employees and presence in over 100 countries, this pharmaceutical company earned about USD 2 Bn. from their three biosimilar drugs which are reportedly MVASI, KANJITNTI, and AMJEVITA.

This pharma giant has also invested about USD 2 Bn. in the development of Biosimilar drugs.

This pharmaceutical company has made Biosimilar drugs primarily in 4 fields which are General Medicine, Oncology, and Hematology along with, Inflammation.

EPOTEIN ALFA

AMJEVITA

AVSOLA

KANJINTI

MVASI

RIABNI

are the various Biosimilar drugs of Amgen. And, STELARA, EYLEA, SOLIRIS are in their pipeline.

Recently Amgen revealed their Biosimilar report’s 8 version. It revealed a major information which said that the pharmaceutical company saved about USD 10 Bn. through their Biosimilar drugs in the past five years.

3.Viartis

Headquartered in Canonsburg, Pennsylvania, this American pharmaceutical company was founded only in 2020 yet they have achieved massive success in the pharmaceutical products with their revenue being USD 16 ~Bn. in 2022.

With presence in 165 countries and with over 45,000 employees worldwide, this pharmaceutical company makes pharmaceutical products in 10 areas which primarily are Cardiovascular, Dermatology, ophthalmology, Oncology, Gastroenterology, Women’s health, Infectious diseases, Diabetes & Metabolism, Immunology, CNS & Anesthesiology, Respiratory diseases and allergy.

Speaking of their first Biosimilar products, their first ever Biosimilar drug was launched in 2014. They have a variety of Biosimilar drugs which are primarily

TRASTUZUMAB

INSULIN ASPART

PEGFILGRASTIM

INSULIN GLARGINE-YFGN

ADALIMUMAB

BEVACIZUMAB

Their Biosimilar drug Insulin Glargine which is known as SEMGLEE was the first ever interchangeable Biosimilar drug in the United States which was FDA approved.

Their PEGFILGRASTIM also was the first ever FDA approved drug in the United States. They have launched their Biosimilar drugs in over 75 markets worldwide.

4.Coherus Biosciences:

Click here to Ask for a Custom Report

Headquartered in Redwood city, California this American pharmaceutical company earned a revenue of almost USD 211 Mn. In 2022.

With presence in over 55 countries and 300+ employees worldwide, this pharmaceutical company makes products in various areas such as solid tumors, non-small lung cancers, nasopharyngeal carcinoma, small cell lung cancer and hepatocellular carcinoma.

Speaking of their Biosimilar drugs, this pharma has been in the field of creating Biosimilar drugs since 2010 which has given them almost 13 years of experience.

This pharmaceutical company also disclosed that it plans to spend at least USD 1 Tn. on medicines worldwide, out of which at least 40% will be spent on Biosimilar drugs.

Their three major Biosimilar drugs which are also FDA approved include UDENCYA, YUSIMRY, and CIMERLI.

Udencya is a Biosimilar drug of Pegfilgrastim, Yusimry is a Biosimilar drug of Ranibizumab, and Cimerli is a Biosimilar drug of Adalimumab.

5.Biogen

Headquartered in Cambridge, Massachusetts, this American pharmaceutical company earned a revenue of around USD 10 Bn. in 2022.

This company happens to have an experience of more than 40 years when it comes to making pharmaceutical products.

With presence in over 80 countries and more than 9000 employees worldwide, this pharmaceutical company primarily deals in Neurology, Specialized Immunology, Neuropsychiatry, Ophthalmology, and Rare Diseases.

ADUCANUMAB

LECANEMAB

TOFERSEN

ZURANOLONE

LITIFILIMAB

BENAPALI

FLIXABI

IMRALDI

are some of their Biosimilar drugs.

With their Biosimilar drugs, more than 250,000 people have gone on Anti-Tumor Necrosis Factor therapy.

Recently, this pharmaceutical company also made an agreement with Bio-Thera solutions to develop a Biosimilar drug for the treatment of Rheumatoid Arthritis.

0 notes

alex121world · 4 years

Text

Affinity Chromatography Resins Market – Survey On Product Awareness 2025

Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/3005

The global affinity chromatography resins market can be segmented on the basis of products, application and region. On the basis of product, the global affinity chromatography resins market can be segmented into synthetic and native. The native product is expected to hold a significant share during the forecast period. On the basis of global application, the affinity chromatography resins market can be segmented into food & beverage, biopharmaceutical industry, and clinical research organizations. The biopharmaceutical application segment is expected to hold the largest share during the forecast period. On the basis of region, the global affinity chromatography resins market can be segmented into North America, Europe, Asia Pacific, Middle East and Africa, and South America. Amongst all, North America and Europe is expected to be the most lucrative affinity chromatography resins market owing to favorable government initiatives and increasing demand in pharmaceutical, biotechnological, and healthcare sector for drug development in the region.

Covid 19 Impact Analysis@

https://www.trendsmarketresearch.com/report/covid-19-analysis/3005

0 notes

pratikwadekar2 · 4 years

Text

PCR Devices Market Strategic Insights and key Business Influencing Factors | Major Players – Thermo Fisher Scientific, QIAGEN, BD, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher, Agilent Technologies, Inc., Siemens, bioMérieux SA.

PCR Devices Market have its applications in DNA sequencing, cloning, library generations, mutagenesis, expression profiling among others. PCR devices are thermal cycler which is commonly used in laboratories for amplifying the segments of DNA through polymerase chain reaction. PCR devices are user friendly and are able to provide quick result. These devices are widely used in the hospital, diagnostic center, pharmaceutical and biotechnology companies, clinical research organizations, academia and laboratories.

Asia-Pacific PCR devices market is registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed due to surging incidences of the infectious diseases and genetic disorders infants is contributing to the growth of the market

Get Sample Report at :

https://www.databridgemarketresearch.com/request-a-sample/?dbmr=asia-pacific-pcr-devices-market

Competitive Analysis: Asia-Pacific PCR Devices Market

Few of the major market competitors currently working in the Asia-Pacific PCR devices market are Abbott, Thermo Fisher Scientific, QIAGEN, BD, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher, Agilent Technologies, Inc., Siemens, bioMérieux SA, Fluidigm Corporation, Promega Corporation, Analytik Jena AG, LGC Limited and Enzo Life Sciences, Inc., among others

Key Pointers Covered in the Asia-Pacific PCR Devices Market Trends and Forecast to 2026

Asia-Pacific PCR Devices Market New Sales Volumes

Asia-Pacific PCR Devices Market Replacement Sales Volumes

Asia-Pacific PCR Devices Market Installed Base

Asia-Pacific PCR Devices Market By Brands

Asia-Pacific PCR Devices Market Size

Asia-Pacific PCR Devices Market Procedure Volumes

Asia-Pacific PCR Devices Market Product Price Analysis

Asia-Pacific PCR Devices Market Healthcare Outcomes

Asia-Pacific PCR Devices Market Cost of Care Analysis

Asia-Pacific PCR Devices Market Regulatory Framework and Changes

Asia-Pacific PCR Devices Market Prices and Reimbursement Analysis

Asia-Pacific PCR Devices Market Shares in Different Regions

Recent Developments for Asia-Pacific PCR Devices Market Competitors

Asia-Pacific PCR Devices Market Upcoming Applications

Asia-Pacific PCR Devices Market Innovators Study

Get Detailed TOC:

https://www.databridgemarketresearch.com/toc/?dbmr=asia-pacific-pcr-devices-market

Scope of the PCR Devices Market

Asia-Pacific PCR Devices Market By Technology (Digital PCR, Real-time PCR), Product Type (Instrument, Reagent, Consumables, Others), Application (Oncology, Blood Testing, Pathogen Detection, Research, Forensic, Others), End User (Hospital, Diagnostic Center, Pharmaceutical and Biotechnology Companies, Clinical Research Organizations, Academia, Laboratories), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific) – Industry Trends and Forecast to 2026

PCR devices have its applications in DNA sequencing, cloning, library generations, mutagenesis, expression profiling among others. PCR devices are thermal cycler which is commonly used in laboratories for amplifying the segments of DNA through polymerase chain reaction. PCR devices are user friendly and are able to provide quick result. These devices are widely used in the hospital, diagnostic center, pharmaceutical and biotechnology companies, clinical research organizations, academia and laboratories.

Research Methodology: Asia-Pacific PCR Devices Market

Global PCR Devices Market is registering a substantial CAGR in the forecast period of 2019-2026. This rise in the market can be attributed due to surging incidences of the infectious diseases and genetic disorders infants is contributing to the growth of the market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Reasons to Purchase this Report:

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/Countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

Speak to Author :

https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=asia-pacific-pcr-devices-market

Key insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

PCR Devices Market Similar Report Here:

Artificial Knee Joint Market

Legal Marijuana Market

#PCR Devices Market #PCR Devices Market share #PCR Devices Market size #PCR Devices Market trends #PCR Devices Market report #PCR Devices Market research #PCR Devices Market news

0 notes

myoliver123stuff · 5 years

Text

Affinity Chromatography Resins Market Overview, Growing Demand and Scope 2018 to 2025

Get Sample Copy Of The Report: https://www.trendsmarketresearch.com/report/sample/3005

Request For Table of Contents: https://www.trendsmarketresearch.com/report/requesttoc/3005

Make an Inquiry before Buying@ https://www.trendsmarketresearch.com/checkout/3005/Single

0 notes

marketreserchnews · 5 years

Text

Multiplex Assays Market Impressive Massive Growth |

Multiplex Assays Market study presents basic data and true figures about the market giving a general assessable analysis of this market based on market drivers, market trends, constraints and its future prospects. The report supplies the worldwide monetary challenge with the help of Porter’s Five Forces Analysis and SWOT Analysis. Some of the prominent participants operating in this market are BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Cepheid, Siemens AG, Hologic Inc., Luminex Corporation. , MESO SCALE DIAGNOSTICS, LLC., QIAGEN, PerkinElmer Inc. , Illumina, Inc. , AGENA BIOSCIENCE, INC. , Olink , Randox Laboratories Ltd., Bio-Techne. , Agilent Technologies, Agilent Technologies, Sysmex Corporation and among others..

Global multiplex assays market is expected to reach a healthy CAGR of 7.5% in the forecast period of 2019 to 2026.

Interesting? Apply for a sample report: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-Multiplex Assays-market

By Products & Services (Reagents & Consumables, Instruments & Accessories, Software & Services), Type (Nucleic Acid Multiplex Assays, Protein Multiplex Assays, Cell-Based Multiplex Assays), Technology (Protein Microarray, Polymerase Chain Reaction, Multiplex Real-Time PCR, Flow Cytometry, Fluorescence Detection, Luminescence, Others), Application (Clinical Diagnostics, Research & Development), End User (Hospitals, Clinical Laboratories, Pharmaceutical & Biotechnology Companies, Research Institutes, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East & Africa)

Multiplex Assays Market Similar Report Here:

Emergency Location Transmitter Market

Wireless Occupancy Sensor Market

Surface Management Temperature Sensor Market

Battery Case Market

GROWING APPLICATIONS OF MULTIPLEX ASSAYS:

Multiplex assays are recently used for several multiplex assays that helps in the detection of different serological markers in the same blood sample that is developed by different research teams based on the Luminex technology. There are various diseases which are detected by multiplex assays and they are diabetes, heart disease, Alzheimer's disease, hypertension, obesity and others.

The Luminex technology is used for the detection of antibodies (Abs) against malaria parasites in blood samples. This assay based on Luminex technology is the first as well as most extensive multiplex assay in malaria serology in the Southeast Asian region. Such technologies for detection purposes can increases the growth of the market. For instance, according to ChildFund, 214 million of the people suffered from malaria worldwide. Many of these are detected by multiplex assays where luminex technology is used.

MILLIPLEX MAP multiplex assay panels by using Luminex xMAP technology is used for detection of cancer biomarker and is one of the flexible, consistent devices in recent time for detection of multiple analyte in single time. A tumor marker or biomarker is a molecular component whose quantity is dissimilar between tumor-bearing and non-tumor-bearing subjects. In oncology field also the multiplex assays is playing a major role inhelping the market to grow as the people nowdays are detected with cancer cases.

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Multiplex Assays Market Competitions, by Manufacturer

4 Global Multiplex Assays Market Analyses by Regions

5 North America Multiplex Assays by Countries

6 Europe Multiplex Assays by Countries

7 Asia-Pacific Multiplex Assays by Countries

8 South America Multiplex Assays by Countries

9 Middle East and Africa Multiplex Assays by Countries

10 Global Multiplex Assays Market Segment by Type

11 Global Multiplex Assays Market Segment by Application

12 Sales Channel, Distributors, Traders and Dealers

13 Research Findings and Conclusion

14 Appendixes

Get Detailed Toc and Charts & Tables@ https://www.databridgemarketresearch.com/toc/?dbmr=global-Multiplex Assays-market

Market Segment by Regions, regional analysis covers:

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia, etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Some of the important question for stakeholders and business professional for expanding their position in the Global Multiplex Assays Market:

Which Region offers the most rewarding open doors for the market in 2019?

What are the business threats and variable scenario concerning the market?

What are probably the most encouraging, high-development scenarios for Multiplex Assays movement showcase by applications, types and regions?

What segments grab most noteworthy attention in Multiplex Assays Market in 2019 and beyond?

Who are the significant players confronting and developing in Multiplex Assays Market?

Buy the Latest Detailed Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-Multiplex Assays-market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Multiplex Assays Market

0 notes

dbmrmarketresearchnews · 5 years

Text

Gene Therapy Market Massive Growth |

Gene Therapy Market taking under consideration the expansion factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Gene Therapy market with the help of research methodologies such as PESTLE and Porter’s Five Forces analysis. Few of the major competitors currently working in the global gene therapy market are Pfizer Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Spark Therapeutics, Inc., bluebird bio, Inc., ALLERGAN, Krystal Biotech, Inc., Amicus Therapeutics, Inc., Sarepta Therapeutics, Novartis AG, MeiraGTx Limited, Rocket Pharmaceuticals, Lonza, Biogen, Gilead Sciences, Inc., REGENXBIO Inc., uniQure N.V., Solid Biosciences Inc., Audentes Therapeutics among others.

Global gene therapy market is rising gradually with a healthy CAGR of 36.1% in the forecast period of 2019-2026.

This Research will help you grow your Business: [Download free Sample PDF of This Research Report]

By Type (Somatic Gene Therapy, Germline Gene Therapy, Others), Gene Type (Antigen, Cytokine, Suicide, Others), Viral Vector (Retroviruses, Herpes Simplex Virus, Adenoviruses, Others), Non-Viral Vector (Naked/Plasmid Vectors, Electroporation and Others), Application (Oncology, Rare Diseases, Infectious Disease, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others)

Market Drivers

Prevailing rate of cancer acts as a market driver in the forecast period

Competition among the leading pharmaceutical companies in the approval of gene therapy products is another factor boosting this market growth

Increasing investment of private and government organization in research and development of gene therapy drives the market growth

Increasing awareness about gene therapy and its applications is another factor boosting this market growth

Market Restraints

High cost associated with the treatment restricts the market growth

Side effects like unwanted immune responses also hampers the market growth

Concerns regarding the unethical use of gene therapy also hamper the market growth

Gene Therapy Market similar report here:

Global Functional Flour Market

Global Fruits and Vegetables Processing Equipment Market

Global Frozen Fruit and Vegetable Processing Market

Global Freeze Dried Fruits & Vegetables Market

Global Food Salt Market

Gene therapy is a technique of insertion of genes into cells and tissues for treatment of any disease. In this technique the defective gene is replaced with a functional gene. It is the strategy of manipulation of expression of specific genes responsible for the disease. This therapy is a promising treatment option for a number of diseases. The application of gene therapy is wide and it is mostly used for treatment of cancer, cystic fibrosis, heart disease, diabetes, AIDS among others.

Table of Contents

1 Market Overview

2 Manufacturers Profiles

3 Global Gene Therapy Market Competitions, by Manufacturer

4 Global Gene Therapy Market Analyses by Regions

5 North America Gene Therapy by Countries

6 Europe Gene Therapy by Countries

7 Asia-Pacific Gene Therapy by Countries

8 South America Gene Therapy by Countries

9 Middle East and Africa Gene Therapy by Countries

10 Global Gene Therapy Market Segment by Type

11 Global Gene Therapy Market Segment by Application

12 Sales Channel, Distributors, Traders and Dealers

13 Research Findings and Conclusion

14 Appendixes

Enquire Here to Get Customization, Methodology & Check Discount for this Report @ CLICK HERE NOW

Important Features that are under offering & key highlights of the report:

Detailed overview of Gene Therapy market

In-depth market segmentation by Type, Application etc.

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Gene Therapy market

Strategies of key players and product offerings

Market player’s information to sustain and enhance their footprint

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Gene Therapy market performance

Changing market dynamics of the industry

Key questions answered

Who are the Leading key players and what are their Key Business plans in the Global Gene Therapy market?

What are the key concerns of the five forces analysis of the Global Gene Therapy market?

What are different prospects and threats faced by the dealers in the Global Gene Therapy market?

What are the strengths and weaknesses of the key vendors?

Buy the Latest Detailed Report @ CLICK HERE NOW

Reasons for Buying this Gene Therapy Report

1. Gene Therapy market report aids in understanding the crucial product segments and their perspective.

2. Initial graphics and exemplified that a SWOT evaluation of large sections supplied from the Gene Therapy industry.

3. Even the Gene Therapy economy provides pin line evaluation of changing competition dynamics and retains you facing opponents.

4. This report provides a more rapid standpoint on various driving facets or controlling Gene Therapy promote advantage.

5. This worldwide Gene Therapy report provides a pinpoint test for shifting dynamics that are competitive.

About Us:

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]

#Gene Therapy Market

0 notes